Non-CME Symposia take place on Sunday and Tuesday.
The ATS encourages ATS 2016 attendees to participate in any of several Non-CME Symposia Sunday and Tuesday.
Sunday
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 5 (Ballroom Level)
Bridging the Evidence: Applying Case-Based Reasoning to Improve Non-Cystic Fibrosis Bronchiectasis Care
The program introduces an exciting learning format that simulates clinical decision making and allows you to compare your clinical impression and management approach to that of the expert faculty.
At the end of this learning activity, participants should able to:
- Understand the impact of non-cystic fibrosis bronchiectasis (NCFB) on patients’ quality-of-life, disease morbidity, and mortality.
- Consider changes in NCFB management strategy in patients who have chronic infection with respiratory pathogens, including but not limited to P. aeruginosa.
- Recognize the short- and long-term impact of NCFB exacerbations including its consequences on quality-of-life, future exacerbations, hospital admissions, and mortality.
Chairman: Timothy Aksamit, MD Rochester, Minnesota.
Speakers: Anne O’Donnell, MD, Washington, D.C.; James Chalmers, MD, Dundee, UK; Patrick Flume, MD, Charleston, South Carolina. Expert Panelists: David Griffith, MD, Tyler, Texas; Adam Hill, MD, Edinburgh, UK; Gregory Tino, MD, Philadelphia, Pennsylvania; Kevin Winthrop, MD, Portland, Oregon
Company: Bayer Pharma AG
6:30-9:30 p.m.
Park Central San Francisco: Metropolitan Ballroom (Second Level)
Burning Questions in COPD and Asthma
(open to non-U.S. attendees only)
How have we progressed in COPD exacerbation risk reduction and what are the implications of the new clinical trial evidence? What are the key targets in allergic asthma and how do new treatments align with different phenotypes?
Join world-renowned experts discussing these burning questions during this symposium.
Speakers:
- Welcome and Introduction—Professor Roland Buhl (Chair, Germany)
- Are burning issues in severe asthma initiated by small sparks?—Professor David Price (Singapore)
- Uncovering the hidden elements of the allergic cascade—Professor Dave Singh (UK)
- Quick-fire presentations: Role of IgE responses in asthma according to disease endo/phenotypes—Professor Dave Singh (UK) and Professor Chanez (France)
- IgE in severe allergic asthma: A strong history and new findings—Professor Pascal Chanez (France)
- Word from the Chair: From asthma to COPD—Professor Roland Buhl (Germany)
- Hot topics in COPD: Why focus on exacerbations?—Professor David Price (Singapore)
- What are we doing to reduce COPD exacerbations?—Professor Dave Singh (UK)
- Shedding further light on COPD exacerbation prevention: New evidence—Professor Claus Vogelmeier (Germany)
- Word from the Chair: The implications of new evidence—Professor Roland Buhl (Germany)
- Time to talk: Burning questions—Chair facilitated panel discussion
- Do we have the answers?—Professor Roland Buhl (Germany)
Company: Novartis Pharma AG
6:30-9:30 p.m.
San Francisco Marriott Marquis: Yerba Buena Ballroom 7 (Lower B2 Level)
A Clinical Discussion on Severe Eosinophilic Asthma and Its Management
A review of considerations in the diagnosis and management of severe eosinophilic asthma.
Speakers: Mario Castro, MD, MPH, FCCP, Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine, Professor of Medicine and Pediatrics, Washington University School of Medicine,
St. Louis, Missouri
Company: TEVA Respiratory
6:30-9:30 p.m.
San Francisco Marriott Marquis: Yerba Buena Ballroom 9 (Lower B2 Level)
Controversies in PAH: Experts Explore Combination Therapy
- 6:30 p.m. Registration and Buffet Dinner
- 7-8:30 p.m. Interactive Session
A faculty of PAH experts will explore developments in PAH therapy, including combination therapy and recent clinical trial data. The program will also feature an interactive patient scenario and allow for audience participation.
Speakers: Theresa De Marco, MD, Director of Advanced Heart Failure and Pulmonary Hypertension, Professor, University of California, San Francisco, School of Medicine, San Francisco, California; Nicholas Hill, MD, Chief, Pulmonary, Critical Care and Sleep Division, Professor, Tufts University School of Medicine, Boston, Massachusetts; Rajan Saggar, MD, Assistant Clinical Professor of Medicine, Pulmonary & Critical Care, University of California, Los Angeles Medical Center, Los Angeles, California
Company: Gilead Sciences Inc.
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 6 (Ballroom Level)
COPD Treatment Options Available Via Ellipta® Inhaler
This interactive dinner program will provide an overview of COPD treatment options available via the Ellipta® inhaler. The presentation will address the rationale for combination therapy in the treatment of COPD and will include clinical trials data, and important safety information as well as a demonstration of the Ellipta® inhaler and examination of the device characteristics and features.
Speakers: Deborah Long, MD, FCCP, U.S. Medical Affairs Lead, GSK, Research Triangle Park, North Carolina; Neil C. Barnes, MD, Medical Head, Global Respiratory Franchise, GSK, Uxbridge, UK
6:30-9:30 p.m.
San Francisco Marriott Marquis: Golden Gate Ballroom B (B2 Level)
Is It Idiopathic Pulmonary Fibrosis? Diagnostic Challenges and Treatment
The process of identifying, diagnosing, and treating idiopathic pulmonary fibrosis (IPF) will be explored by a multidisciplinary panel of expert faculty, including a pulmonologist, radiologist, and a pathologist. The use of OFEV® (nintedanib) for the treatment of patients with IPF will also be reviewed.
Speakers: Marilyn K. Glassberg, MD, Professor of Medicine, Surgery, and Pediatrics, University of Miami Miller School of Medicine; Mark Rumbak, MD, Professor, College of Medicine, Internal Medicine University of South Florida; Sudhakar Pipavath, MD, Associate Professor, Radiology, University of Washington; Kirk Jones, Professor, Pathology, UCSF School of Medicine
Company: Boehringer Ingelheim Pharmaceuticals Inc.
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 4 (Ballroom Level)
Evolving Science in the Management of COPD
This non-CME dinner symposium will offer novel insights into the latest research in inhaled respiratory medication in COPD.
Speakers: Bartolome Celli (Chair), U.S.; Klaus F. Rabe, Germany; Leonardo M. Fabbri, Italy; Gary T. Ferguson, U.S.; Fernando J. Martinez, U.S.
Company: AstraZeneca Pharmaceuticals Inc.
6:30-9:30 p.m.
San Francisco Marriott Marquis: Golden Gate Ballroom A (B2 Level)
Expert Perspectives: Idiopathic Pulmonary Fibrosis (IPF) Dinner Symposium
Join three esteemed IPF experts as they share their perspectives on the diagnosis and management of IPF at this dinner symposium. These IPF experts will engage participants in a series of presentations on topics such as making an early diagnosis, the efficacy and safety profile of an FDA-approved therapy, and effectively managing the IPF patient.
Company: Genentech Inc.
6:30-9:30 p.m.
InterContinental San Francisco: Grand Ballroom (Third Level)
Introducing a New Treatment Option for PAH: A Case-based Discussion
The science behind pulmonary arterial hypertension (PAH) continues to evolve. This interactive, case-based symposium will feature a panel of experts who will introduce a new option for the treatment of patients with PAH.
Dinner will be provided. Dinner will not be provided to physicians and other healthcare professionals licensed in Vermont or other states where gifts and meals are prohibited.
Speakers: Vallerie McLaughlin, MD, Program Chair, University of Michigan Health System, Ann Arbor, Michigan; Nick Kim, MD, University of California, San Diego, La Jolla, California; Victor Tapson, MD, Cedars-Sinai Medical Center, Los Angeles, California
Company: Actelion Pharmaceuticals US Inc.
6:30-9:30 p.m.
Hilton Union Square: Imperial Ballroom (Ballroom Level)
Sarcoidosis: A Multidisciplinary Approach to Diagnosis and Management
(open to U.S. attendees only)
The current state of sarcoidosis diagnosis and management will be discussed. Topics will include:
- Introduction to Sarcoidosis, Marc A. Judson, MD
- Cardiac Sarcoidosis, TBD
- Neurosarcoidosis, Jinny Tavee, MD
- Ocular Sarcoidosis, James Rosenbaum, MD
- Pulmonary Sarcoidosis, Robert P. Baughman, MD
- Therapy for Symptomatic Sarcoidosis, Robert P. Baughman, MD
Dinner will be provided.
Company: Mallinckrodt Pharmaceuticals
8:30-10:30 p.m. Dessert Symposium
San Francisco Marriott Marquis: Mezzanine (Second Level)
Joint Presentation on Seasonal Allergic Rhinitis and Maintenance Treatment of Asthma
Meda Pharmaceuticals will host a joint presentation on Seasonal Allergic Rhinitis and maintenance treatment of Asthma. A donation of $75 will be made to The ATS Foundation for each registered ATS attendee attending this Non-CME Symposium.
Speakers: William E. Berger, MD, MBA, University of California Irvine, Mission Viejo, California; Randall W. Brown, MD, MPH, AE-C, University of Michigan, Ann Arbor, Michigan; Bradley Chipps, MD, Capital Allergy & Respiratory Disease Center, Sacramento, California; LeRoy Graham, MD, Bridge Atlanta Medical Group, Atlanta, Georgia; Michael G. Marcus, MD, Maimonides Medical Center, Brooklyn, New York; Kevin R. Murphy, MD, Boys Town National Research Hospital, Omaha, Nebraska; David P. Skoner, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania; Maeve O’Connor, MD, Allergy Asthma & Immunology Relief, Charlotte, North Carolina
Company: MEDA Pharmaceuticals Inc.
Tuesday
6:30-9:30 p.m.
San Francisco Marriott Marquis: Golden Gate Ballroom A (B2 Level)
Do You Know Your Asthma Patients’ Phenotypes?
(open to non-U.S. attendees only)
Chaired by Professor Eric D. Bateman, an internationally renowned faculty will discuss the impact of asthma pathophysiology on approaches to management, barriers to improving control of symptomatic asthma, and the evidence for using anticholinergic bronchodilator therapy for asthma. Attendance at this symposium is for non-U.S. health care professionals only.
Speakers:
- Professor Eric D. Bateman (South Africa) [Chair]
- Professor Christian Taube (the Netherlands)
- Professor Huib Kerstjens (the Netherlands)
- Professor William Busse (United States)
Company: Boehringer Ingelheim Pharma GmbH & Co. KG
6:30-9:30 p.m.
San Francisco Marriott Marquis: Yerba Buena Ballroom 7 (Lower B2 Level)
Evolving Perspectives in Asthma Heterogeneity: The Role of Eosinophils
This non-CME dinner symposium will explore current and emerging scientific concepts in asthma heterogeneity and the role of eosinophils in uncontrolled asthma.
Speakers:
- Bartolome Celli, U.S. (Chair)
- Unmet Need in Uncontrolled Asthma and Barriers to Improved Outcomes (~30 mins) Mark FitzGerald (Canada)
- Cellular and Molecular Endotypes and Phenotypes in Uncontrolled Asthma (~30 mins) Parameswaran Nair (Canada)
- The Biology and Role of Eosinophils in Uncontrolled Asthma (~30 mins) Andrew Menzies-Gow (UK)
- Understanding Disease Heterogeneity and the Importance of Biomarkers (~30 mins) Rey Panettieri (U.S.)
Company: AstraZeneca Pharmaceuticals Inc.
6:30-9:30 p.m.
San Francisco Marriott Marquis: Yerba Buena Ballroom 9 (Lower B2 Level)
Fixed Dose LAMA/LABA Inhalers in COPD: What the Trials Tell Us
Evidence increasingly supports a prominent role for fixed-dose combinations of long-acting muscarinic antagonists and long-acting ß2-agonists (LAMA/LABA) in the management of patients with COPD. This interactive symposium will present the latest efficacy and safety data of new and emerging fixed-dose LAMA/LABA combinations, including application to specific patient case scenarios.
Speaker: Chair: Richard H. Casaburi, MD, MEng, PhD
Company: The France Foundation (supported by a grant from Boehringer Ingelheim Pharmaceuticals Inc.)
6:30-9:30 p.m.
San Francisco Marriott Marquis: Golden Gate Ballroom B (B2 Level)
Holding Court in PAH
Experience the drama and excitement of Holding Court in PAH, as some of the most challenging treatment issues are argued by leading experts in pulmonary hypertension. With the honorable judge Lewis Rubin, MD presiding, you the jury will deliberate the evidence, then cast your vote for a winner. Register at www.pah.tv.
Speakers: (Chair) Lewis J. Rubin, MD, APMC, Professor of Medicine, Pulmonary and Critical Care Division, Director, PAH Program UC San Diego School of Medicine, San Diego, California. Faculty: Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, Massachusetts; Martha Kingman Liberty, FNP-C, DNP, Nurse Practitioner, Pulmonary Services, Heart & Lung Center, UT Southwestern Medical Center, Dallas, Texas; Richard A. Krasuski, MD, FACC, FAHA, FESC, Professor of Medicine and Pediatrics, Director of the Adult Congenital Heart Disease Center, Director of Hemodynamic Research, Duke University Medical Center, Durham, North Carolina; Vallerie McLaughlin, MD; Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Dept. of Internal Medicine/Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan; Ioana Preston, MD, Associate Professor of Medicine, Pulmonary Function Lab Director, Director, Pulmonary Hypertension Center, Tufts University School of Medicine, Boston, Massachusetts; Rajan Saggar, MD, Assistant Clinical Professor of Medicine, Pulmonary & Critical Care, Director of the Medical Intensive Care Unit, Heart-Lung Transplant & Pulmonary Hypertension Programs, Ronald Reagan UCLA Medical Center, Los Angeles, California; Sean Studer, MD, MSc, Chief of Medicine, NYU-Woodhull Medical Center, New York, NY; Victor Tapson, MD, Professor of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, California
Company: PAH.TV (supported by an unrestricted educational grant from Actelion Pharmaceuticals)
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 6 (Ballroom Level)
IPF Case Discussions: What Have We Learned After 18 Months With Pirfenidone and Nintedanib?
Supported by an independent grant, this highly interactive activity will focus on how the multidisciplinary team works together to manage patients with IPF. Experts will dissect and debate cases that illustrate clinical quandaries not addressed by recent clinical studies. This interactive learning format will enhance the learners’ ability to apply knowledge and expert experience to clinical practice. Participants can register for a select few spots to meet in small groups with the faculty, immediately following the symposium, to discuss their own clinical cases.
Speakers: Chair—Paul W. Noble, MD, Chair, Department of Medicine, Director, Women’s Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California; Alison G. Wilcox, MD, FSCCT, Associate Professor of Radiology and Internal Medicine, Section Chief, Cardiothoracic Imaging, Medical Director, Imaging, Keck Hospital of USC, Keck Medical Center of USC, Los Angeles, California; Professor Luca Richeldi, MD, PhD, Professor of Respiratory Medicine, Chair of Interstitial Lung Disease, University of Southampton, UK
Company: The France Foundation (supported by grants from Boehringer Ingelheim Pharmaceuticals Inc. and Genentech Inc.)
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 5 (Ballroom Level)
NTM—A Patient-Centered Approach to Evaluation and Management
Join us for a dinner program that will examine the patient’s journey to diagnosis, the current treatment paradigm, and strategies for managing comorbid conditions in patients with nontuberculous mycobacterial (NTM) lung disease. The program will conclude with a question-and-answer session with the expert faculty panel.
Company: Insmed Inc.
6:30-9:30 p.m.
Hilton Union Square: Continental Ballroom 4 (Ballroom Level)
The Role of Eosinophils in the Management of Severe Asthma
This complimentary dinner program will provide an overview of the pathogenesis of an unmet need in severe asthma. Information regarding the role of eosinophils and the changing landscape in the management of severe asthma will be reviewed.
Speakers: Mark S. Forshag, MD, MHA, U.S. Medical Affairs Lead, GSK, Research Triangle Park, North Carolina; Peter Howarth, MD, Global Medical Expert, GSK, Brentford, UK
Company: GlaxoSmithKline
More Clinical Info
To learn about additional clinical trial research, look for large signs in the Clinical Trials Awareness Area listing current clinical trials in progress from both participating exhibitors and the ATS Corporate Members. To obtain more information, scan the QR codes next to each one.